The role of biomarkers and dosimetry parameters in overall and progression free survival prediction for patients treated with personalized Y glass microspheres SIRT: a preliminary machine learning study.

Journal: European journal of nuclear medicine and molecular imaging
PMID:

Abstract

BACKGROUND: Overall Survival (OS) and Progression-Free Survival (PFS) analyses are crucial metrics for evaluating the efficacy and impact of treatment. This study evaluated the role of clinical biomarkers and dosimetry parameters on survival outcomes of patients undergoing Y selective internal radiation therapy (SIRT).

Authors

  • Zahra Mansouri
    Department of Biomedical Engineering and Medical Physics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Yazdan Salimi
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
  • Ghasem Hajianfar
    Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran.
  • Nicola Bianchetto Wolf
    Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospital, CH-1211, Geneva, Switzerland.
  • Luisa Knappe
    Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospital, CH-1211, Geneva, Switzerland.
  • Genti Xhepa
    Service of Radiology, Geneva University Hospital, CH-1211, Geneva, Switzerland.
  • Adrien Gleyzolle
    Service of Radiology, Geneva University Hospital, CH-1211, Geneva, Switzerland.
  • Alexis Ricoeur
    Service of Radiology, Geneva University Hospital, CH-1211, Geneva, Switzerland.
  • Valentina Garibotto
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland.
  • Ismini Mainta
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland.
  • Habib Zaidi
    Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211, Geneva 4, Switzerland. habib.zaidi@hcuge.ch.